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Abstract
Background: Despite tremendous progress in understanding the mechanisms of constitutive and
alternative splicing, an important and widespread step along the gene expression pathway, our
ability to deliberately regulate gene expression at this step remains rudimentary. The present study
was performed to investigate whether a theophylline-dependent "splice switch" that sequesters the
branchpoint sequence (BPS) within RNA-theophylline complex can regulate alternative splicing.
Results: We constructed a series of pre-mRNAs in which the BPS was inserted within theophylline
aptamer. We show that theophylline-induced sequestering of BPS inhibits pre-mRNA splicing both
in vitro and in vivo in a dose-dependent manner. Several lines of evidence suggest that theophylline-
dependent inhibition of splicing is highly specific, and thermodynamic stability of RNA-theophylline
complex as well as the location of BPS within this complex affects the efficiency of splicing inhibition.
Finally, we have constructed an alternative splicing model pre-mRNA substrate in which
theophylline caused exon skipping both in vitro and in vivo, suggesting that a small molecule-RNA
interaction can modulate alternative splicing.
Conclusion: These findings provide the ability to control splicing pattern at will and should have
important implications for basic, biotechnological, and biomedical research.
Background
Pre-mRNA splicing is a fundamental process that joins
exons by catalyzing the removal of intervening sequences
(introns) from mRNA precursors. Pre-mRNAs are spliced
in a two-step pathway catalyzed by the spliceosome, a
dynamic macromolecular machinery consisting of five
small nuclear ribonucleoproteins (U1, U2, U4, U5 and
U6 snRNPs) and many non-snRNP proteins. In the first
step, pre-mRNA is cleaved at the 5' splice site (ss) generat-
ing two splicing intermediates: a linear first exon, and an
intron-second exon in a lariat configuration. In the second
step, the 3'-hydroxyl group of the last nucleotide in first
exon makes a nucleophillic attack at the phosphodiester
bond separating the intron and the second exon (3' ss),
enabling the joining of two exons and release of the intron
as a lariat (for review, see references [1-3]).
The differential joining of 5' and 3' ss of a single pre-
mRNA, a phenomenon known as alternative splicing, can
generate variant mRNAs with diverse and often antagonis-
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tic functions [4-7]. Alternative splicing of pre-mRNA is
now considered to be the most important source of pro-
tein diversity in vertebrates [8,9]. It is estimated that 35–
60% of human genes generate transcripts that are alterna-
tively spliced [10,11], and 70–90% of alternative splicing
events affect coding capacity of genes [12,13]. Impor-
tantly, deregulated splice variant expression has been
identified as the cause of a number of genetic disorders
[14-16], and certain forms of cancer have been linked to
unbalanced isoform expression from genes involved in
cell cycle regulation or apoptosis [17-20]. Given the criti-
cal role of alternative splicing in a variety of cellular proc-
esses, strategies that could influence pre-mRNA splicing
decisions will have far-reaching effects in biotechnology
and medicine.
Initial efforts aimed at controlling pre-mRNA splicing
exploited the intrinsic property of nucleic acids to bind
specific pre-mRNA sequence and inhibit splicing [21].
However, susceptibility of antisense oligonucleotides to
nuclease digestion, off-target effects, difficulty with deliv-
ery and localization led to the realization that improved
methods are required [22]. Bifunctional molecules that
function like an antisense oligonucleotide, but carry the
binding site for a known splicing factor have proved to be
useful in reprogramming pre-mRNA splicing [23-25].
While bifunctional molecules have overcome some of the
problems of the original antisense-based approach,
requirements of chemical modifications limit their utility.
In addition, these approaches function in a constitutive
manner, i.e., an antisense oligonucleotide directed to
inhibit the splicing of a pre-mRNA will continue to do so
as long as the oligonucleotide is available. Since alterna-
tive splicing of many pre-mRNAs is controlled by splicing
regulators [6,26], a small molecule ligand that could
mimic the function of a splicing regulator would be of
broad general application in controlling gene expression
[27].
We have previously shown that insertion of a theophyl-
line-responsive riboswitch into the 3' ss region of a model
pre-mRNA enables its splicing to be repressed during the
second step specifically by theophylline [28]. Since the
vast majority of human genes are alternatively spliced and
splice site pairing in general occurs at early stages of the
splicing pathway, we reasoned that sequestering of BPS in
a theophylline aptamer would be a better approach for
controlling alternative splicing. In this study, we tested
this idea by constructing a series of pre-mRNAs in which
BPS was inserted within theophylline aptamer. We show
that theophylline-induced sequestering of BPS is highly
specific and inhibits pre-mRNA splicing both in vitro and
in vivo in a dose dependent manner. Our results indicate
that the thermodynamic stability of RNA-theophylline
complex and the location of BPS within this complex
affect the efficiency of splicing inhibition. Finally, we
show that sequestering of BPS within RNA-theophylline
complex can modulate alternative splicing both in vitro
and in cultured cells.
Results
Insertion of BPS within theophylline-responsive riboswitch 
confers ligand dependent control of splicing
To investigate whether theophylline-induced sequestering
of BPS would allow conditional control of splicing, we
constructed a series of AdML pre-mRNA derivatives in
which BPS was embedded within high-affinity theophyl-
line binding aptamer (TBA) (Fig. 1A and see Additional
File 1). These pre-mRNAs differ in terms of the distance of
aptamer sequence from the 3' ss AG. 32P-labeled pre-
mRNAs were transcribed as runoff transcripts using T7
RNA polymerase and gel purified RNAs were incubated in
HeLa nuclear extract under the conditions that support in
vitro splicing. The results presented in Fig. 1B demonstrate
that these substrates underwent normal splicing, albeit
with lower efficiency compared with the parent pre-
mRNA (Fig. 1B compare lane 2 with lanes 5, 7 and 9). Sig-
nificantly, splicing reactions performed in the presence of
theophylline gave rise to lower yields of spliced mRNA,
suggesting that theophylline-mediated sequestering of
branchpoint inhibits pre-mRNA splicing (Fig. 1B, com-
pare lanes 5, 7 and 9 with lanes 6, 8 and 10, respectively).
Quantitation of these data indicate that theophylline
inhibited the splicing of AdBPT pre-mRNAs by ~65–90%,
but had no effect on the splicing of AdML 21AG, a pre-
mRNA that does not contain theophylline-binding
aptamer (Fig. 1C). We chose AdBPT15AG for further
experiments because of its better splicing efficiency in the
absence of theophylline; while 17% of AdBPT15AG pre-
mRNA was converted into mRNA, only ~7% and 9% of
AdBPT12AG and AdBPT18AG pre-mRNAs gave rise to
spliced product, respectively.
To determine theophylline concentration that may be
optimum for inhibiting pre-mRNA splicing, 32P-labeled
AdBPT15AG pre-mRNA was subjected to in vitro splicing
in the presence of increasing concentrations of theophyl-
line. Results shown in Fig. 1D indicate that theophylline
inhibited the splicing of AdBPT15AG pre-mRNA in a
dose-dependent manner with an IC50 value 0.5 ± 0.1 mM.
A slight increase in the splicing efficiency at lower concen-
tration of theophylline may be the RNA stabilization
rather than inhibitory effect of the ligand.
Splicing inhibition through theophylline-induced 
sequestering of BPS is specific
Our model of conditional control of splicing specifies that
theophylline inhibits pre-mRNA splicing by binding to its
cognate sequence, thereby sequestering the BPS within
RNA-theophylline complex. To confirm that the splicingBMC Molecular Biology 2008, 9:23 http://www.biomedcentral.com/1471-2199/9/23
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Insertion of BPS within theophylline-responsive riboswitch confers ligand-dependent control of splicing Figure 1
Insertion of BPS within theophylline-responsive riboswitch confers ligand-dependent control of splicing. (A) 
Schematic diagram of AdBPT pre-mRNAs. Underlined sequence and encircled adenosine residue represents the BPS and 
branch nucleotide, respectively. Open boxes represent exon sequences and horizontal lines between exons indicate introns. 
Arrow specifies 5' and 3' splice sites. The boxed residues within the secondary structure of theophylline binding aptamer are 
conserved for theophylline binding. The numbering system follows according to the reference [29]. (B) In vitro splicing of 
AdML 21AG and AdBPT pre-mRNAs. 32P-labeled pre-mRNAs were incubated in HeLa nuclear extracts at 30°C for 2 h in the 
absence or presence of theophylline (for experimental details, see methods section). Total RNA isolated from each reaction 
was fractionated on a 13% polyacrylamide denaturing gel. The bands corresponding to pre-mRNA substrates, intermediates 
and spliced products are indicated on the right. M, Century™-plus RNA size marker (Ambion). Asterisk (*) indicates degraded 
lariat. (C) Histogram depicting the effect of theophylline on the splicing of AdML 21AG and AdBPT pre-mRNAs. Splicing was 
calculated as the ratio of spliced mRNA to the total and normalized to the control (no theophylline). Data represent mean ± 
standard error of the mean (SEM) of three independent experiments. Asterisk represents significant change as compared to 
the control (*, P < 0.0005). (D) Theophylline inhibits the splicing of AdBPT15AG pre-mRNA in a dose-dependent manner. 32P-
labeled AdBPT15AG pre-mRNA was incubated in HeLa nuclear extracts in the absence or with increasing concentration of 
theophylline for 2 h as described in (B). % Splicing calculated as described above and plotted against theophylline (mM). The val-
ues are expressed as mean ± SEM.BMC Molecular Biology 2008, 9:23 http://www.biomedcentral.com/1471-2199/9/23
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inhibition shown in Fig. 1B is specific, we performed the
following experiments. First, we constructed
MAdBPT15AG pre-mRNA that harbors mutations in the
core of TBA, but otherwise is identical to AdBPT15AG
(Fig. 2A, changed nucleotides shown in bold). On the
basis of previously published reports [29,30], which sug-
gest that the 15-nucleotide motif (Fig. 1A, residues
enclosed in box) is essential for high-affinity theophylline
binding, we predicted the splicing of MAdBPT15AG to
remain unaltered in the presence of theophylline. Indeed,
results shown in Fig. 2B demonstrate that theophylline
failed to inhibit the splicing of MAdBPT15AG pre-mRNA.
In contrast, a similar concentration of theophylline was
found to inhibit the splicing of AdBPT15AG (compare
lanes 7 and 8 in Fig. 1B with lanes 2 and 3 in Fig. 2B). Rel-
atively low splicing efficiency of MAdBPT15AG pre-
mRNA in the absence of theophylline suggests that muta-
tions in the core of TBA although prevented theophylline
binding, apparently this did not completely abolish sec-
ondary structure of the aptamer. Support for this interpre-
tation comes from a web-based RNA-folding program
indicating that the mutated aptamer can fold into a sec-
ondary structure (see Additional File 2).
Next, we generated AdT+10 pre-mRNA in which TBA was
relocated upstream of BPS and analyzed its splicing in
vitro using HeLa nuclear extract. As illustrated in Fig. 2C,
this pre-mRNA underwent normal splicing in the pres-
ence of theophylline, suggesting that sequestering of BPS
within RNA-theophylline complex is necessary for splic-
ing inhibition. Finally, we examined the splicing of
AdBPT15AG pre-mRNA in the presence of caffeine, a
purine that is similar in shape and size to theophylline.
Consistent with our previously published observation
Theophylline-dependent inhibition of pre-mRNA splicing is specific Figure 2
Theophylline-dependent inhibition of pre-mRNA splicing is specific. (A) The diagram of MAdBPT15AG pre-mRNA. 
The nucleotide residues shown in bold have been mutated to prevent the binding of theophylline. The RNA secondary struc-
ture is adapted from Zucker's M-FOLD program [62] (see Additional File 2). (B) Theophylline failed to inhibit the splicing of a 
substrate (MAdBPT15AG) that contains mutations within aptamer core. 32P-labeled MAdBPT15AG pre-mRNA was subjected 
to in vitro splicing in the absence (lane 2) or presence of theophylline (lanes 3) for 2 h. The extracted RNA was fractionated on 
a 13% polyacrylamide denaturing gel. The bands corresponding to splicing substrates, intermediates and spliced products are 
indicated on right. The % splicing calculated as in Fig. 1 and values are expressed as mean ± SEM. (C) AdT+10, a pre-mRNA in 
which theophylline-binding aptamer was inserted upstream of BPS was constructed as described in methods. 32P-labeled 
AdT+10 pre-mRNA was subjected to in vitro splicing in the absence (lane 1) or presence of theophylline (lane 2) for 2 h. The 
extracted RNA was fractionated on a 13% polyacrylamide denaturing gel (details as in Fig. 1B).BMC Molecular Biology 2008, 9:23 http://www.biomedcentral.com/1471-2199/9/23
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[28], caffeine failed to exert any influence on the splicing
of AdBPT15AG pre-mRNA (data not shown). Taken
together, we conclude that theophylline-dependent inhi-
bition of pre-mRNA splicing is highly specific.
Insertion of BPS in theophylline-binding aptamer does not 
activate cryptic branchpoint
Previous studies have shown that cryptic branchpoint acti-
vation allows accurate in vitro splicing of mammalian pre-
mRNAs albeit with lower efficiency [31-33]. To determine
if relatively lower splicing efficiency of AdBPT15AG pre-
mRNA is due to the activation of a cryptic branchpoint, we
mapped the position of the RNA branch. Preparative
amounts of lariat intermediates were isolated from in
vitro splicing reaction of AdBPT15AG pre-mRNA per-
formed in the absence or presence of theophylline. The
branchpoint was mapped by the primer extension of
untreated or S100 treated lariat intermediate, which
allows debranching of the lariat RNA [34]. The position of
reverse transcriptase stop site was assigned by using a
dideoxy-sequencing ladder from the parental DNA.
The primer extension analysis of AdBPT15AG pre-mRNA
derived lariat intermediate showed a single stop immedi-
ately before the branchpoint adenosine (Fig. 3, 101 nt
product in lane 6). This band was not detected with
unspliced pre-mRNA (data not shown) or the lariat inter-
mediate that was treated with S100 extract (Fig. 3, lane 7).
In contrast, the primer extension of S100 treated lariat
species generated a 221 nt band corresponding to the size
of linear intron-Exon 2 RNA (Fig. 3, compare lane 6 and
7). Importantly, the lariat intermediate isolated from the-
ophylline treated splicing reaction gave rise to a single
reverse transcriptase stop signal corresponding to 101 nt
(Fig. 3, compare lane 6 with 8). In addition, this lariat
intermediate was S100 sensitive, and the primer extension
of debranched lariat intermediate produced a 221 nt spe-
cies (Fig. 3, lane 8 and 9). The bands marked with asterisk
are the primer extension products of S100 RNA likely gen-
erated due to the non-specific binding of the primer. This
interpretation is supported by the fact that primer exten-
sion of RNA isolated from S100 extract resulted in identi-
cal reverse transcriptase stops (Fig. 3, compare lanes 7 and
9 with lane 10). We conclude that theophylline-depend-
ent sequestering of BPS does not activate cryptic branch-
point.
Thermodynamic stability of lower theophylline aptamer 
stem and location of BPS affects splicing inhibition
Biochemical and structural studies showed that the lower
theophylline aptamer stem is not critical for ligand bind-
ing [29,35], but affects the stability of RNA-theophylline
complex. If true, then altering the length of lower theo-
phylline aptamer stem is expected to affect splicing sup-
pression. To test this idea, we constructed two
AdBPT15AG derivatives in which the length of lower the-
ophylline aptamer stem was either decreased to a single
bp (AdBPT15AG-1S) or increased to eight bp
(AdBPT15AG-8S) (Fig. 4A). To assess the consequences of
varied lower theophylline aptamer stem on pre-mRNA
splicing,  32P-labeled substrates were incubated in HeLa
nuclear extract in the absence or presence of theophylline
under splicing conditions. We found that compared to
~60% splicing repression with AdBP15AG substrate, the-
ophylline inhibited the splicing of AdBPT15AG-8S and
AdBPT15AG-1S pre-mRNAs by ~75% and 25%, respec-
tively (Fig. 4B, compare lanes 1, 3 and 5 with lanes 2, 4
and 6, respectively). These results indicate a direct correla-
tion between the thermodynamic stability of lower theo-
phylline aptamer stem and efficiency of splicing
repression. It is worth mentioning here that although
increasing the length of the lower aptamer stem resulted
in stronger inhibition of splicing, stem >10 bp could
inhibit splicing even in the absence of theophylline (Kim
and Gaur, unpublished results).
To examine whether the location of BPS within the
aptamer affects efficiency of splicing inhibition, we con-
structed a model pre-mRNA in which BPS was inserted in
the lower aptamer stem (Fig. 5A, AdBPT15AG-LS). Results
presented in Fig. 5B demonstrate that relocation of BPS to
the lower stem rendered host pre-mRNA less responsive to
theophylline-mediated inhibition of splicing (compare
lanes 5 and 6 in Fig. 4B with lanes 1 and 2 in Fig. 5B).
Quantitation of the data indicate that compared to ~75%
splicing inhibition with AdBPT15AG-8S, theophylline
inhibited AdBPT15AG-LS pre-mRNA splicing by ~40%.
The efficiency of splicing repression by theophylline is not
significantly different between AdBP15AG and
AdBPT15AG-LS pre-mRNAs, even though the latter con-
tains a thermodynamically more stable lower stem (com-
pare lanes 3 and 4 in Fig. 4B with lanes 1 and 2 in Fig. 5B).
Based on these results, we propose a direct correlation
between the thermodynamic stability of lower theophyl-
line aptamer stem and efficiency of repression, provided
the branchpoint sequence is present in the upper stem.
Theophylline-dependent control of alternative splicing in 
vitro
Naturally occurring RNA structure elements [36-39] as
well as artificial stem-loop structures [28,40-43] are
known to influence splice site choice. To determine
whether theophylline-induced secondary structure could
influence alternative splicing, we constructed a series of
pre-mRNAs comprising of three exons interrupted by two
introns (Fig. 6A and Additional File 1). The sequence
encompassing exon 1, intron 1 and exon 2 is identical to
AdBPT15AG-8S, whereas sequence downstream of exon 2
5' ss is from pRG1, an adenovirus major late pre-mRNA
derivative [44] (Fig. 6A). In addition, these pre-mRNAsBMC Molecular Biology 2008, 9:23 http://www.biomedcentral.com/1471-2199/9/23
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Insertion of BPS in theophylline-binding aptamer does not activate cryptic branchpoint Figure 3
Insertion of BPS in theophylline-binding aptamer does not activate cryptic branchpoint. Lariat intermediate iso-
lated from preparative splicing reactions of AdBPT15AG pre-mRNA performed in the absence (lanes 6 and 7) or presence of 
theophylline (lanes 8 and 9) was subjected to branchpoint mapping. Primer extension was performed on intact (lane 6, -S100) 
or debranched lariat intermediate (lanes 7 and 9, +S100). Asterisks (*) represent primer extension products from S100 total 
RNA (lane 10). The primer extension products were separated on a 13% denaturing polyacrylamide gel. The dideoxy-sequenc-
ing ladder from parental DNA is shown in lanes 2–5. M, 10 bp DNA ladder (Invitrogen).BMC Molecular Biology 2008, 9:23 http://www.biomedcentral.com/1471-2199/9/23
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differ from each other in terms of the strength of exon 2 5'
ss, which increases in the order: ABT0M< ABT2M<
ABT4M< ABT6M [45]. We hypothesized that sequestering
of intron 1 branchpoint by theophylline would allow
intron 2 branchpoint to choose between the 5' ss of exon
1 and 2 for the first step of splicing. Thus, depending upon
which of the two 5' ss is utilized will determine the
amount of exon 2 included/excluded mRNA.
To test this hypothesis, radioactively labeled ABT0M-6M
pre-mRNAs were transcribed and incubated in HeLa
nuclear extract in the absence or presence of theophylline
Thermodynamic stability of lower theophylline aptamer stem affects splicing inhibition Figure 4
Thermodynamic stability of lower theophylline aptamer stem affects splicing inhibition. (A) Schematic diagram of 
AdBPT pre-mRNAs exhibiting varying length of lower aptamer stem. The encircled adenosine residue represents branch nucle-
otide. The distorted hairpin loop structure is the simplified secondary structure of theophylline aptamer. The horizontal lines 
in aptamer lower stem represent hydrogen bonds between complementary bases. (B) The splicing of AdBPT15AG pre-mRNA 
with lower aptamer stem of 4 bp (shown in Fig. 1A) was compared with substrates in which the stem was either decreased to 
a single bp (AdBPT15AG-1S) or increased to eight bp (AdBPT15AG-8S). 32P-labeled pre-mRNAs were subjected to in vitro 
splicing for 2 h in the absence (lanes 1, 3 and 5) or presence of theophylline (lanes 2, 4 and 6) as described in Fig. 1. The 
extracted RNAs were fractionated on a 13% denaturing polyacrylamide gel. The % splicing calculated as in Fig. 1 and values are 
expressed as mean ± SEM.BMC Molecular Biology 2008, 9:23 http://www.biomedcentral.com/1471-2199/9/23
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The location of branchpoint sequence affects efficiency of splicing inhibition Figure 5
The location of branchpoint sequence affects efficiency of splicing inhibition. (A) Schematic representation of 
AdBPT15AG-LS pre-mRNA. The branchpoint sequence is present in the lower aptamer stem and the length of stem is 8 bp. 
(B) 32P-labeled AdBPT15AG-LS pre-mRNA was incubated in HeLa nuclear extract for 2 h in the absence (lanes 1) or presence 
of theophylline (lanes 2) as described in Fig. 1. The extracted RNA was fractionated on a 13% polyacrylamide denaturing gel. 
Percent splicing calculated as in Fig. 1 and values are expressed as mean ± SEM.BMC Molecular Biology 2008, 9:23 http://www.biomedcentral.com/1471-2199/9/23
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as described earlier. Splicing of ABT0M substrate gave rise
to two spliced products (also see below), a slower migrat-
ing band of ~150 nt and an additional band of ~100 nt
(Fig. 6B, lane 1). To determine the identity of these
mRNAs, representative bands were excised and RNA was
subjected to RT-PCR followed by DNA sequencing. The
sequencing results (not shown) indicated that the slower
migrating band represents full-length mRNA, whereas
faster moving band represents exon 2-skipped mRNA gen-
erated as a result of alternative splicing. Notably, theo-
phylline shifted the splicing of ABT0M pre-mRNA in favor
of exon 2 excluded isoform by repressing the activation of
intron 1 branchpoint. This is evident by a sharp decline in
the amount of full-length mRNA and concomitant
Theophylline can modulate alternative splicing in vitro Figure 6
Theophylline can modulate alternative splicing in vitro. (A) Schematic representation of three-exon pre-mRNA sub-
strates with varying strength of exon 2 5' ss. The sequence of first two exons and the entire intron 1 is identical to 
AdBPT15AG-8S. The sequence downstream of intron 2 5' ss, including BPS and exon 3 is from pRG1 [44]. The relative 
strength of exon 2 5' ss described here was based on the published report [45]. (B) Splicing in vitro of the panel of substrates 
(shown in A) displaying the effect of theophylline on the alternative splicing of exon 2. 32P-labeled AdML0M-6M pre-mRNAs 
were subjected to in vitro splicing in the absence (lanes 1, 3, 5 and 7) or presence of theophylline (lanes 2, 4, 6 and 8) as 
described in Fig. 1. The extracted RNA was fractionated on a 13% polyacrylamide denaturing gel. Other labeling is as in Fig. 1. 
The internal exon 2 exclusion: inclusion ratio for each substrate in the absence or presence of theophylline is shown below 
each lane.BMC Molecular Biology 2008, 9:23 http://www.biomedcentral.com/1471-2199/9/23
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increase of intron 1-retained mRNA (Fig. 6B, compare
~304 nt band and full length mRNA in lane 1 and 2). Fur-
ther examination of these results across ABT0M to ABT6M
panel indicate theophylline-dependent increase in the
amount of intron 1-retained mRNA, and progressively
weak suppression of exon 2-included mRNA (Fig. 6B,
note the amounts of these mRNAs from left to right in the-
ophylline treated lanes). While an increase in the amount
of intron 1-containing mRNA is due to the inhibition of
intron 1 excision, increasingly weak suppression of exon
2 included mRNA is the result of a gradual increase in the
strength of exon 2 5' ss, which promotes exon 2 inclusion.
These data indicate 2–3 fold increase in exon 2 excluded:
included mRNA ratio across the panel (Fig. 6B). We also
observed the presence of intron 1 containing mRNA in
reactions where theophylline was excluded. This could
simply be the result of lower efficiency of intron 1 exci-
sion, which was also observed in case of constitutively
spliced substrate (Fig. 4B).
Theophylline-dependent control of alternative splicing in 
vivo
To determine whether theophylline-induced sequestering
of branchpoint can control splicing in living cells, we
inserted the DNA that encodes ABT4M pre-mRNA into the
mammalian expression vector pcDNA 3.1/ Myc-His(-) C
yielding pcABT4M. A mutant (pcABT4Mmu) that does
not bind to theophylline was also constructed. Next, HeLa
cells were transfected transiently with pcABT4M,
pcABT4Mmu or empty vector and treated with theophyl-
line or buffer. After 24 h incubation, cells were harvested,
and total RNA was isolated. Reverse transcription fol-
lowed by PCR shown in Figure 7A demonstrates that the-
ophylline can regulate the alternative splicing of ABT4M
pre-mRNA. In contrast, theophylline had a less significant
effect on the splicing of ABT4Mmu pre-mRNA, suggesting
that binding of theophylline to its cognate RNA is neces-
sary for controlling alternative splicing (Figure 7A, com-
pare lanes 4 and 5 with lanes 6 and 7; also see Fig. 7B). We
note that theophylline-dependent decrease in exon 2
included mRNA is not accompanied by a corresponding
increase in exon 2 skipping. This suggests that although a
block in the assembly of components involved in proxi-
mal 3' ss recognition prevented exon inclusion, the effect
was not strong enough to influence a switch in splice site
choice.
Discussion
We have previously shown that insertion of 3' ss AG
within a theophylline aptamer inhibits pre-mRNA splic-
ing at the second step specifically by theophylline [28].
Since selection of BPS is made during early stages of the
splicing pathway, we reasoned that sequestering of BPS
within RNA-theophylline complex might be an effective
strategy for controlling alternative splicing.
To test this hypothesis, we constructed a series of model
pre-mRNAs in which BPS was engineered to be part of the-
ophylline-binding aptamer (Fig. 1A). We found that these
substrates underwent normal splicing, albeit with lower
efficiency, when incubated with HeLa nuclear extract. Sig-
nificantly, splicing of these substrates was inhibited spe-
cifically by theophylline (Fig. 1B). The observed low
efficiency of splicing of these substrates could be due to a
relatively long BPS-to-poly-(U) distance and/or the effect
of purine residues that separate BPS from the poly-(Y)
tract; both of these factors have been shown to affect lariat
formation and exon ligation [46]. Indeed, relocation of
BPS into lower aptamer stem, which decreased BPS-to-
poly-(U) distance as well as excluded purine residues,
improved splicing efficiency (compare the amount of lar-
iat product and mRNA in Fig. 5B and Fig. 1B). In addition,
unavailability of a competing BPS likely forced the splic-
ing machinery to select a structured branchpoint, thus
affecting the splicing efficiency. Support for this explana-
tion comes from a previously reported study in which
sequestering of a splice site within artificial hairpin
sequence was found to be less detrimental to the splicing
provided an alternative splice site is available [40].
Given the affinity (equilibrium dissociation constant or
Kd) of theophylline for cognate RNA aptamer is ~0.3 mM
[29], an incomplete splicing inhibition at 2.0 mM theo-
phylline is intriguing (Fig. 1B). We can offer the following
explanations to this observation. First, the kinetic effect
likely prevented RNA-theophylline complex from com-
plete inhibition of splicing. It has been previously
reported that the association kinetics of theophylline-
aptamer binding is more than 1000-times slower than a
diffusion controlled rate, which makes the conforma-
tional change in aptamer the rate limiting step for the for-
mation of RNA-theophylline complex [47]. Thus, even
though 2.0 mM theophylline is expected to saturate RNA
aptamer, the slow association kinetics likely prevented
complete splicing inhibition. Second, differential require-
ment of Mg2+ for binding of theophylline to its cognate
RNA and in vitro splicing may be the reason for incom-
plete splicing repression. Whereas efficient binding of the-
ophylline to RNA aptamer requires 5.0 mM Mg2+ [29,48],
~3.0 mM Mg2+ has been found optimum for in vitro splic-
ing [49]. Therefore, the residual splicing could be the
result of a thermodynamically less stable RNA-theophyl-
line-complex. Third, it is possible that theophylline also
binds to other cellular factor(s), which may not affect
splicing, but could decrease the amount of available theo-
phylline. Nevertheless, theophylline dependent inhibi-
tion of splicing is highly specific (Fig. 2) and is carried out
within the range of concentrations that has been reported
in other studies. For example, An et al showed that 1–10
mM theophylline is required to affect the cleavage of an
aptamer-fused shRNA by Dicer [50]. Similarly, translationBMC Molecular Biology 2008, 9:23 http://www.biomedcentral.com/1471-2199/9/23
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repression of a CAT reporter containing theophylline-
binding aptamer in wheat germ extracts required 1 mM
theophylline [51].
Our data suggest that the size of lower theophylline
aptamer stem as well as the location of BPS within
aptamer affects the degree of splicing inhibition. For
example, increasing the length of lower theophylline
aptamer stem from a single to eight bp improved the effi-
ciency of splicing inhibition by ~3-fold (Fig. 4B), suggest-
ing a linear relationship between the length of the stem
and the percent splicing inhibition. The insertion of BPS
within lower theophylline aptamer stem although
improved splicing efficiency, it also rendered pre-mRNA
to be less responsive to theophylline-dependent splicing
inhibition (cf. Fig. 4B, lane 5 and Fig. 5B lane 1). The most
straightforward explanation to this observation is that
when present in the aptamer lower stem, the accessibility
of BPS to the spliceosome is energetically more favorable
compared to its presence in the upper stem whose
unwinding may require additional ~8.9 kcal/mole [52],
the binding energy of theophylline to RNA aptamer.
Differential BPS recognition plays an important role in
the regulation of alternative splicing [53,54]. For example,
a splicing suppressor element that binds to SR proteins,
3RE, has been shown to regulate adenovirus major late
IIIa pre-mRNA alternative splicing by preventing the bind-
ing of U2 snRNP to the BPS [55,56]. Here in this study we
have shown that theophylline induced sequestering of
BPS can influence alternative splicing both in vitro and in
cultured cells (Fig. 6 and 7). Our data suggest that theo-
phylline-mediated exon 2 skipping is due to intron 1
branchpoint sequestration, which allows intron 2 branch-
point to attack two alternative 5' splice sites for step I of
the splicing. Two lines of evidence support this interpreta-
tion. First, splicing of ABT0M-6M pre-mRNAs yielded
intron 1-retained mRNAs whose amount increased in the
presence of theophylline (Fig. 6B, RNA moving just above
300 nt size marker). Second, theophylline shifted splicing
in favor of exon 2 excluded mRNA by enabling intron 2
branchpoint to attack exon 1 5' ss. This effect is more pro-
nounced in ABT4M where the strength of exon 2 5' ss is
moderate; a very weak and a very strong exon 2 5' ss is
expected to be skipped or included, respectively. An alter-
native explanation for theophylline-mediated exon 2
skipping is the process of exon definition. In this scenario
sequestering of intron 1 branchpoint may interfere in the
recognition of exon 2 3' ss, which in turn may compro-
mise U1 snRNP binding to the downstream 5' ss resulting
in exon skipping.
Quantitative analysis of data indicated that theophylline
shifted exon 2 excluded/exon 2 included mRNA ratio
between 2 to 3-fold in all of the tested substrates. It is
important to point out that alternative splicing typically
involves relatively small (< 10-fold) changes in isoform
ratio, and the observed changes in the splice variant ratios
may prove to be ideal for controlling the splicing of many
biologically important pre-mRNAs. Although the present
work represents only a proof-of-principle study, this sys-
tem can be further fine-tuned to influence alternative
splicing. For example, simultaneous sequestration of
intron 1 branchpoint sequence and the 5' splice site of
exon 2 has the potential to alter the splice variant ratio by
several fold.
A previous report by Solnick and Lee analyzing the splic-
ing pattern of artificial RNA secondary structure indicates
that inverted repeat inhibits splicing in vitro, but failed to
exert any effect in vivo unless the size of the stem is more
than 50 nucleotides of perfect complementarity [57].
Theophylline-mediated modulation of alternative splicing in  vivo Figure 7
Theophylline-mediated modulation of alternative 
splicing in vivo. (A) HeLa cells were transiently transfected 
with empty vector, pcABT4M or pcABT4Mmu (containing 
mutations within core TBA). Cells were treated with buffer 
(lanes 4 and 6) or with 1 mM theophylline (lanes 5 and 7). 
The product of RT-PCR assays of total RNA isolated from 
each well was analyzed on a 2.5% agarose gel to estimate the 
effect of theophylline on the efficiency of exon 2 alternative 
splicing. The PCR amplified bands corresponding to exon 2 
included or excluded mRNA is indicated. (B) The internal 
exon 2 exclusion: inclusion ratio for ABT4M or ABT4Mmu in 
the absence (open box) or presence of theophylline (shaded 
box) is shown. The data represent mean ± SEM. * P < 0.04 
versus mutant is significant.BMC Molecular Biology 2008, 9:23 http://www.biomedcentral.com/1471-2199/9/23
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How, then, does theophylline induced secondary struc-
ture with a significantly short stem size compared with the
one employed by these authors could influence splicing
in vivo? This could be attributed to the intricate network
of hydrogen bonds and stacking interactions that locks
theophylline into the aptamer core thereby providing sta-
bility to the RNA secondary structure [35]. Since RNA sec-
ondary structure formed in Solnick and Lee study does not
appear to be bound by a small molecule or a protein, the
cellular RNA unwinding activity could have destabilized
RNA secondary structure allowing normal splicing. Alter-
natively the use of larger loop size by Solnick and Lee
could have allowed assembly of splicing factors on the
nascent RNA while the other half of the inverted repeat is
undergoing transcription [42].
Conclusion
In conclusion, we have demonstrated that the RNA affin-
ity of theophylline can be exploited to develop a system
for conditional control of splicing. The modulation of
mRNA splicing by theophylline offers several advantages.
For example, theophylline-mediated control of splicing is
flexible and can regulate splicing before or after the com-
pletion of the first step [28]. The fact that theophylline is
a known drug with favorable pharmacokinetics and cellu-
lar uptake properties, this provides the possibility for con-
trolling splicing of a trans gene in a gene therapy setting
where the target gene expression could be controlled in a
ligand-dependent manner.
Methods
Plasmid Construction
Plasmids encoding AdBPT12AG, 15AG and 18AG pre-
mRNAs are derivatives of pAdMLPar [58] and were con-
structed following PCR-based cloning. In the first step, the
sequence encompassing Hind III-Sal I region of pAdML-
Par was replaced by the sequence (5'-
AAGCTTTCGGGTGATACCAGTCAGCGTCTTGCTGAC-
CCTTGGCAGCACCTTTTTTCAGGTCGAC-3') using PCR
based mutagenesis with oligonucleotides #35745 (5'-
CCTTGGCAGCACCTTTTTTCAGGTCGACGTTGAG-
GACAAAC-3') and 35744 (5'-GTCAGCAAGACGCT-
GACTGGTATCACCCGAAAGCTTCAAGGAAAC-3') as
forward and reverse primers, respectively. The amplified
DNA was then circularized using T4 DNA ligase to yield
plasmid pAdBPT9AG. In the second step, PCR amplifica-
tion of pAdBPT9AG using oligonucleotide T7 (5'-
TAATACGACTCACTATAGGG-3') as forward primer and
oligonucleotide #37457 (5'-AACGTCGACCTGAAAAAAA
AAGGTGCTGCCAAGGGTCAG-3'), or oligonucleotide #
37458 (5'-AACGTCGACCTGAAAAAAAAAGAAGGTGCT-
GCCAAGGGTCAG-3') or #37459 (5'-AACGTCGACCTG
AAAAAAAAAGAAAAAGGTGCTGCCAAGGGTCAG-3') as
reverse primer yielded DNA fragments containing EcoR I
and Sal I restriction sites. Finally, EcoR I and Sal I digested
DNA fragments were introduced into pAdMLPar back-
bone to yield the desired constructs. Plasmids
pMAdBPT15AG and pAdBPT15AG-1S were constructed
by modified site-directed mutagenesis [59] consisting of
two PCR amplification steps. In the first step, T7 oligonu-
cleotide and the mutagenic primer #44300 (5'-
TTCCTTGAAGCTTTCGGGTGGATGGTGTCAGCGTCTT-
GCTGACCCT-3') or oligonucleotide #37460 (5'-
CAACGTCGACCTGAAAAAAAAAGCTGCCAA
GGGTCAGCAAGACGCTGACTGGTATCGAAAGCTTCAA
GGAAACCC-3') was used as forward and reverse primer,
respectively. In the second PCR, the product of the first
PCR served as the forward primer and SP6 (5'-ATTTAGGT-
GACACTATAGAA-3') as reverse primer. The construction
of pAdBPT15AG-8S was carried out by PCR using
pAdML21AG as template and oligonucleotide #38219(5'-
TCTTGCTGACCCTTGGCAGCTCCTTCTTTTTTTTTCAG-
GTCGACG-3') and oligonucleotide #38221 (5'-CGCTGA
CTGGTATCTCCTTCTCGAAAGCTTCAAGGAAACCC-3')
as forward and reverse primers, respectively. The resulting
DNA fragments were circularized by T4 DNA ligase. To
create pAdBPT15AG-LS, site-directed mutagenesis using
T7 as forward primer, oligonucleotide SP6 as reverse
primer and oligonucleotide #39393 (5'-
TTGAAGCTTTCGGTCAGCAGATACCAGCATCGTCTTGA
TGCCCTTGGCAGCTGCTGACTTTTTTTCTTTTTTTT-
TCAGGT-3') as mutagenic primer was used. The resulting
DNA fragment was digested with EcoR I and Xba I, and
cloned into pSP72 vector.
To generate alternative splicing constructs, 3' half of pRG1
[44] was PCR amplified using oligonucleotide #39559
(5'-ATCGCGGATCCGTGGTGTGTCCTAGCATGTA-
GAACTGGTTACC-3'), or #39561 (5'-
ATCGCGGATCCGTGGTGGGTCCTAGCATGTAGAACT-
GGTTACC-3'), or #39562 (5'-ATCGCGGATCCGTGGT-
TAGTCCTAGCATGTAGAACTGGTTACC-3'), or #39563
(5'-ATCGCGGATCCGAGGTTGGTCCTAGCATGTA-
GAACTGGTTACC-3') as forward primer and oligonucle-
otide #39368 (5'-TAGAGGATCCCCACTGGAAAGACCG-
3') as reverse primer, respectively. The PCR amplified
DNA was subjected to BamH I digestion followed by sub-
cloning into pAdBPT15AG to yield plasmids pABT0M-
6M. In vivo splicing constructs (pcABT0M-6M) were gen-
erated by subcloning the PCR amplified DNA encoding
pre-mRNAs ABT0M-6M into Nhe I and Xba I digested
pcDNA 3.1/ Myc-His(-) C The oligonucleotide #40550
(5'-ATAGGGAGACCGGCGCTAGCCCGCATCGCTGTCT-
GCGAGGG-3') and SP6 were used as forward and reverse
primers, respectively. The construction of pcABT4Mmu
was carried out following site-directed mutagenesis with
oligonucleotide T7 as forward primer, oligonucleotide
#46436 (5'-CCTTGAAGCTTTCGAGAAGGAGGATGGT-
GTCAGCGTCTTGCTGACCCTTGG-3') as mutagenic
primer, and oligonucleotide #44759 (5'-TCAATGATGAT-BMC Molecular Biology 2008, 9:23 http://www.biomedcentral.com/1471-2199/9/23
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GATGATGATGG-3') as reverse primer and pcABT4M as
template. The PCR amplified DNA was subcloned into
Nhe I and EcoR I digested pcDNA 3.1/ Myc-His(-) C vec-
tor.
Cell culture and transfection
HeLa cells were grown in Dulbecco's modified Eagle
medium (Cellgro, Herndon, VA) supplemented with L-
glutamine and 10% (v/v) fetal bovine serum (Omega sci-
entific, Tarzana, CA). Cells were maintained under stand-
ard incubation conditions (humidified atmosphere, 95%
air, 5% CO2, 37°C). For transfection, 4.5 × 105 cells were
seeded in a 6-well plate a day prior to transfection. Cells
were grown to approximately 60–70% confluencey and
transfected with 1 µg of DNA by using Lipofectamine
2000 (Invitrogen) according to the manufacturer's proto-
col except that prior to the addition of DNA-Lipo-
fectamine 2000 complex, the media was replaced by fresh
media containing indicated concentration of theophyl-
line (≥ 99.0%, Fluka). A freshly prepared solution of the-
ophylline (25 mM stock solution in sterile water) was
used.
RNA Isolation and RT-PCR
Total RNA was prepared using RNeasy mini kit (Qiagen)
and treated with DNase I (Roche) following the manufac-
turer's protocol. Five microgram RNA was subjected to
reverse transcription using oligo (dT) and MMLV reverse
transcriptase (Invitrogen) essentially according to the
manufacturer's instructions. Next, 1 µl of RT mixture was
PCR amplified using oligonucleotide #43573 (5'-
GGGCCAGCTGTTGGGGTCGA-3') and #43754 (5'-
GGGCCAGCTGTTGGGCTCGC-3') as forward primer and
oligonucleotide #39368 as common reverse primer. The
PCR products were analyzed by electrophoresis on 8%
polyacrylamide or 2.5% agarose gel, and quantified by
ImageJ software version 1.36b (National Institutes of
Health).
In vitro transcription
Linearized plasmid (1 µg) was used as template for run-off
transcription [60]. A typical (12.5-µL) in vitro transcrip-
tion reaction consisted of 40 mM Tris-HCl (pH 8.0), 2.0
mM spermidine, 10 mM DTT, 20 mM MgCl2, NTP mix-
ture (0.4 mM CTP and ATP, and 0.1 mM GTP and UTP),
2.0 mM cap analog (NEB), ~10 µCi [∝-32P] UTP, 10–20
units T7 polymerase (NEB). After incubation at 37°C for
2 h, the reaction was terminated by adding 12.5 µL stop
buffer and RNA was purified on a 8% denaturing polyacr-
ylamide gel.
In vitro splicing
HeLa-S3 cells for nuclear extracts were purchased from the
National Cell Culture Center (Cellex Biosciences, Minne-
apolis, MN) received as cell pellet on wet ice. Nuclear
extracts were prepared as described [61]. Splicing assays
were performed in 12.5-µL reaction mixtures containing
50% nuclear extract. To ensure that theophylline binds to
its RNA target, a solution consisting of 32P-labeled pre-
mRNA (5–10 fmol, ~10,000 cpm per reaction), indicated
concentration of theophylline, 0.5 µl BC300 (20 mM
HEPES, pH 8.0, 20% glycerol, 300 mM KCl, 0.2 mM
EDTA) and 0.25 µl 160 mM MgCl2 was heated at 65°C for
5 min, followed by 20 min incubation at room tempera-
ture. Next, 0.5 mM ATP, 20 mM creatine phosphate, 0.4
units of RNasin (Promega), 1.0 mM DTT, 6.25 µl HeLa
nuclear extract, and water up to 12.5 µl (all concentrations
are final) was added and incubation continued at 30°C
for the indicated time. Where indicated, theophylline was
substituted by caffeine or water. To terminate the splicing
reaction, 87.5 µl proteinase K buffer consisting of 25 µg
proteinase K (Roche), 100 mM Tris-HCl, pH 7.5, 12.5 mM
EDTA, pH 8.0, 150 mM NaCl and 1% SDS was added and
incubated at 55°C for 15 min. After phenol-chloroform
extraction, the extracted RNAs were resolved by electro-
phoresis on 13% (19:1) 7M-urea polyacrylamide gel (or
as indicated in the figure legends), visualized and quanti-
fied using a Molecular Dynamics PhosphorImager and the
ImageQuant version 4.2 software.
Branchpoint mapping
Branchpoint mapping was performed essentially accord-
ing to the published protocol [34]. Preparative scale (100
µl) splicing reactions were performed as described earlier
and lariat intermediates were visualized by autoradiogra-
phy. After gel elution, one half of the lariat intermediate
was subjected to debranching reaction with S100 extract.
The branchpoint was mapped by comparing the primer
extension products of the lariat intermediate and S100
treated lariat intermediate. In brief, 10–15 pmol R5
primer (5'-ATGCCTGCAGGTCGACTCTAGAGG-3') was
5' end labeled with [ϒ-32P]ATP by incubating at 37°C in
the presence of 20 U of T4 polynucleotide kinase (NEB)
and 1× kinase buffer (NEB). Unincorporated [ϒ-32P]ATP
was removed by using MicroSpin G-25 Sephadex column
(GE Healthcare). Intact or debranched lariat RNA and ~1
pmole labeled primer were mixed in 20 µl of high salt
buffer containing 40 mM PIPES (pH 6.4), 1 mM EDTA,
400 mM NaCl and 0.2% SDS. Primer was annealed to lar-
iat intermediate by heating at 95°C for 1 min and slow
cooling to room temperature over a period of 30–60 min.
Reaction mixture was extracted with phenol:chloroform
followed by ethanol precipitation. The RNA-primer
hybrid was resuspended in 10 µl reaction buffer contain-
ing 50 mM Tris (pH 8.0), 74 mM KCl, 6 mM MgCl2, 10
mM DTT, 1 mM each dNTPs, 1µl of AMV reverse-tran-
scriptase (Invitrogen) and incubated for 1 h at 42°C. Sam-
ples were treated with 1 µl of DNase free RNase I (NEB)
for 40 min at 37°C. Next, reaction mixture was extracted
with phenol:chloroform, ethanol precipitated, and resus-BMC Molecular Biology 2008, 9:23 http://www.biomedcentral.com/1471-2199/9/23
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pended in loading buffer. A sequencing ladder was gener-
ated using a Sequnase version 2.0 DNA sequencing kit, the
parental plasmid and the R5 primer. The products were
analyzed on a 13% polyacrylamide denaturing gel.
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